RE:News ..... Lots of Meh, agree. It is good to know what is going on with some of the other pipelines as well. I did pick up that they have plenty of contingency in place to ensure they keep supplying product to R&F, and it's apparent now Wanbang is part/assisting with this multi party effort on pet therapy which tells us that the remain fully engaged.
I keep coming back to their focus right now on negotiations with this Top 10. It looks pretty obvious at this point they don't need more money between revenue flow, options and cashed warrants. If they did they would have signalled that clearly.
From a market segment point of view, It looks to me like global market for dyschromia would be covered by this avenue but a more generalized lightener would be for the asiatic region using Tfc 1394. Or maybe the Top 10 would do both if that was on the table? We will probably know whenever they update on that.